Breast Biopsy Needle Shortage Crisis
Key Questions
What caused the current breast biopsy needle shortage?
The FDA issued an alert following a Hologic recall due to particulate contamination risks. The shortage is expected to last through Q1 2027 and affects key devices used in breast cancer diagnosis.
How are radiology practices responding to the biopsy needle shortage?
The ACR has issued urgent guidance recommending conservation strategies, prioritizing high-risk patients, and shifting to alternative methods like ultrasound-guided biopsies. This helps maintain workflow while minimizing disruptions.
Who is most impacted by the breast biopsy needle shortage?
Women with dense breasts needing MRI-guided biopsies face the greatest challenges, as the shortage exacerbates existing access gaps. It also delays cancer diagnosis pathways overall.
What is the expected duration of the biopsy needle shortage?
The shortage is projected to extend through the first quarter of 2027. Health systems are advised to implement long-term mitigation plans.
What alternatives are recommended during the needle shortage?
Providers should prioritize high-risk cases and use alternative biopsy techniques such as ultrasound or other needle types. These steps aim to preserve diagnostic capacity amid the Hologic recall.
FDA alerts on shortage of breast biopsy needles due to Hologic recall (particulate contamination). ACR issues urgent letter to members. Shortage expected to extend through Q1 2027. Conservation strategies recommended, including prioritizing high-risk patients and using alternative biopsy methods. This disrupts cancer diagnosis workflow, especially for women with dense breasts requiring MRI-guided biopsy, and exacerbates access gaps. Confirmed by recent article.